Compare Mesoblast Limited (MESO) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Ulta Beauty Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Ulta Beauty Inc trades at $563.56 (market cap $24.12B). The key difference: Ulta Beauty Inc is far larger — about 13.8× Mesoblast Limited's market cap, and Ulta Beauty Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Ulta Beauty Inc for 92 Days on average.
| MESO | ULTA | |
|---|---|---|
Market Cap | $1.75B | $24.12B |
Volume | 239,027 | 457,598 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $706.82 |
52-Week Low | $13.19 | $450.75 |
Typical Hold Time | 14 Days | 92 Days |
Enterprise Value | $1.83B | $26.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
ULTA stock trades at $545.48, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings that beat estimates and raised its 2026 outlook, driven by e-commerce growth. Key financials show robust profitability with a 9.34% net income margin and 46.12% ROE, though revenue growth has moderated recently. Analyst sentiment is positive with a consensus price target of $624.93, implying potential upside from current levels.
The outlook for ULTA is favorable, supported by raised guidance and strategic initiatives in omnichannel and wellness categories. Investment opportunities include valuation expansion if execution meets raised expectations. Key risks include margin pressure from promotions, flat store traffic, and competitive pressures in the beauty retail space that could challenge future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
